General Information of the Protein
Protein ID
PT00858
Protein Name
Protein kinase C alpha type
Gene Name
PRKCA
Secondarily
Gene Name
PKCA
PRKACA
Sequence
MADVFPGNDSTASQDVANRFARKGALRQKNVHEVKDHKFIARFFKQPTFCSHCTDFIWGFGKQGFQCQVCCFVVHKRCHEFVTFSCPGADKGPDTDDPRSKHKFKIHTYGSPTFCDHCGSLLYGLIHQGMKCDTCDMNVHKQCVINVPSLCGMDHTEKRGRIYLKAEVADEKLHVTVRDAKNLIPMDPNGLSDPYVKLKLIPDPKNESKQKTKTIRSTLNPQWNESFTFKLKPSDKDRRLSVEIWDWDRTTRNDFMGSLSFGVSELMKMPASGWYKLLNQEEGEYYNVPIPEGDEEGNMELRQKFEKAKLGPAGNKVISPSEDRKQPSNNLDRVKLTDFNFLMVLGKGSFGKVMLADRKGTEELYAIKILKKDVVIQDDDVECTMVEKRVLALLDKPPFLTQLHSCFQTVDRLYFVMEYVNGGDLMYHIQQVGKFKEPQAVFYAAEISIGLFFLHKRGIIYRDLKLDNVMLDSEGHIKIADFGMCKEHMMDGVTTRTFCGTPDYIAPEIIAYQPYGKSVDWWAYGVLLYEMLAGQPPFDGEDEDELFQSIMEHNVSYPKSLSKEAVSVCKGLMTKHPAKRLGCGPEGERDVREHAFFRRIDWEKLENREIQPPFKPKVCGKGAENFDKFFTRGQPVLTPPDQLVIANIDQSDFEGFSYVNPQFVHPILQSAV
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Kinase
>
Protein Kinase
>
AGC protein kinase group
>
AGC protein kinase PKC family
>
AGC protein kinase PKC alpha subfamily
Function
Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. Involved in cell proliferation and cell growth arrest by positive and negative regulation of the cell cycle. Can promote cell growth by phosphorylating and activating RAF1, which mediates the activation of the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which facilitates active cyclin-dependent kinase (CDK) complex formation in glioma cells. In intestinal cells stimulated by the phorbol ester PMA, can trigger a cell cycle arrest program which is associated with the accumulation of the hyper-phosphorylated growth-suppressive form of RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti-apoptotic function in glioma cells and protects them from apoptosis by suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia cells mediates anti-apoptotic action by phosphorylating BCL2. During macrophage differentiation induced by macrophage colony-stimulating factor (CSF1), is translocated to the nucleus and is associated with macrophage development. After wounding, translocates from focal contacts to lamellipodia and participates in the modulation of desmosomal adhesion. Plays a role in cell motility by phosphorylating CSPG4, which induces association of CSPG4 with extensive lamellipodia at the cell periphery and polarization of the cell accompanied by increases in cell motility. During chemokine-induced CD4(+) T cell migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting in its dissociation from LRCH1 and the activation of GTPase CDC42 (PubMed:28028151). Is highly expressed in a number of cancer cells where it can act as a tumor promoter and is implicated in malignant phenotypes of several tumors such as gliomas and breast cancers. Negatively regulates myocardial contractility and positively regulates angiogenesis, platelet aggregation and thrombus formation in arteries. Mediates hypertrophic growth of neonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA treatment, is required to induce cardiomyocyte hypertrophy up to heart failure and death, by increasing protein synthesis, protein-DNA ratio and cell surface area. Regulates cardiomyocyte function by phosphorylating cardiac troponin T (TNNT2/CTNT), which induces significant reduction in actomyosin ATPase activity, myofilament calcium sensitivity and myocardial contractility. In angiogenesis, is required for full endothelial cell migration, adhesion to vitronectin (VTN), and vascular endothelial growth factor A (VEGFA)-dependent regulation of kinase activation and vascular tube formation. Involved in the stabilization of VEGFA mRNA at post-transcriptional level and mediates VEGFA-induced cell proliferation. In the regulation of calcium-induced platelet aggregation, mediates signals from the CD36/GP4 receptor for granule release, and activates the integrin heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. During response to lipopolysaccharides (LPS), may regulate selective LPS-induced macrophage functions involved in host defense and inflammation. But in some inflammatory responses, may negatively regulate NF-kappa-B-induced genes, through IL1A-dependent induction of NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which modulates EIF4G1 binding to MKNK1 and may be involved in the regulation of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of KIT activity. Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription. Phosphorylates SOCS2 at 'Ser-52' facilitating its ubiquitination and proteasomal degradation (By similarity). Phosphorylates KLHL3 in response to angiotensin II signaling, decreasing the interaction between KLHL3 and WNK4 (PubMed:25313067).
    Show/Hide
Uniprot ID
Primary ID:
P17252

Secondarily ID:
B5BU22
Q15137
Q32M72
Q96RE4
    Show/Hide
Ensembl ID
ENSG00000154229
HGNC ID
HGNC:9393
Subcellular Location
Cytoplasm
Cell membrane
Mitochondrion membrane
Nucleus
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000013 , Sf9
Compound ID Compound Name Compound Formula
CP0040333
2-{[2,6-dihydroxy-4-({[(3R,4R)-4-[(4-hydroxybenzene)amido]pyrrolidin-3-yl]oxy}carbonyl)phenyl]carbonyl}-3-hydroxybenzoic acid
   Show/Hide
C26H22N2O10
 1
1
IC50 = 22 nM
   TI
   LI
   LO
   TS
CP0040070
2-{[2,6-dihydroxy-4-({[(1R,2R)-2-[(4-hydroxybenzene)amido]cyclopentyl]oxy}carbonyl)phenyl]carbonyl}-3-hydroxybenzoic acid
   Show/Hide
C27H23NO10
 1
1
IC50 = 40 nM
   TI
   LI
   LO
   TS
CP0038373
2-{[2,6-dihydroxy-4-({[(3R,4R)-3-[(4-hydroxybenzene)amido]azepan-4-yl]oxy}carbonyl)phenyl]carbonyl}-3-hydroxybenzoic acid
   Show/Hide
C28H26N2O10
 1
1
IC50 = 74 nM
   TI
   LI
   LO
   TS
CP0372635
(3R,4R)-4-[(4-hydroxybenzene)amido]pyrrolidin-3-yl 4-[(2-{[(acetyloxy)methoxy]carbonyl}-6-hydroxyphenyl)carbonyl]-3,5-dihydroxybenzoate
   Show/Hide
C29H26N2O12
 1
1
IC50 = 130 nM
   TI
   LI
   LO
   TS
CP0398629
(3R,4R)-4-[(4-hydroxybenzene)amido]pyrrolidin-3-yl 4-{[2-({[(2,2-dimethylpropanoyl)oxy]methoxy}carbonyl)-6-hydroxyphenyl]carbonyl}-3,5-dihydroxybenzoate
   Show/Hide
C32H32N2O12
 1
1
IC50 = 160 nM
   TI
   LI
   LO
   TS
CP0495469
(3R,4R)-4-[(4-hydroxybenzene)amido]pyrrolidin-3-yl 3,5-dihydroxy-4-{[2-hydroxy-6-(methoxycarbonyl)phenyl]carbonyl}benzoate
   Show/Hide
C27H24N2O10
 1
1
IC50 = 250 nM
   TI
   LI
   LO
   TS
CP0391277
(1R,2R)-2-[(4-hydroxybenzene)amido]cyclopentyl 4-{[2-(ethoxycarbonyl)-6-hydroxyphenyl]carbonyl}-3,5-dihydroxybenzoate
   Show/Hide
C29H27NO10
 1
1
IC50 = 920 nM
   TI
   LI
   LO
   TS
CP0405218
(3R,4R)-4-[(4-hydroxybenzene)amido]pyrrolidin-3-yl 4-{[2-(ethoxycarbonyl)-6-hydroxyphenyl]carbonyl}-3,5-dihydroxybenzoate
   Show/Hide
C28H26N2O10
 1
1
IC50 = 2200 nM
   TI
   LI
   LO
   TS
CP0405508
(3R,4R)-4-[(4-hydroxybenzene)amido]pyrrolidin-3-yl 4-{[2-(butoxycarbonyl)-6-hydroxyphenyl]carbonyl}-3,5-dihydroxybenzoate
   Show/Hide
C30H30N2O10
 1
1
IC50 = 3100 nM
   TI
   LI
   LO
   TS
CP0487436
(1R,2R)-2-[(4-hydroxybenzene)amido]cyclopentyl 3,5-dihydroxy-4-({2-hydroxy-6-[(propan-2-yloxy)carbonyl]phenyl}carbonyl)benzoate
   Show/Hide
C30H29NO10
 1
1
IC50 = 4700 nM
   TI
   LI
   LO
   TS
CP0405497
(3R,4R)-4-[(4-hydroxybenzene)amido]pyrrolidin-3-yl 4-({2-[(cyclohexylmethoxy)carbonyl]-6-hydroxyphenyl}carbonyl)-3,5-dihydroxybenzoate
   Show/Hide
C33H34N2O10
 1
1
IC50 = 17000 nM
   TI
   LI
   LO
   TS
CP0419325
(3R,4R)-4-[(4-hydroxybenzene)amido]pyrrolidin-3-yl 3,5-dihydroxy-4-({2-hydroxy-6-[(2-methylpropoxy)carbonyl]phenyl}carbonyl)benzoate
   Show/Hide
C30H30N2O10
 1
1
IC50 = 19000 nM
   TI
   LI
   LO
   TS
CP0382649
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-methylamino]ethoxy]ethoxy]ethoxy]ethyl]propanamide
   Show/Hide
C50H56BF2N7O7
 1
1
Kd = 43 nM
   TI
   LI
   LO
   TS
CP0382724
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]amino]ethoxy]ethoxy]ethoxy]ethyl]propanamide
   Show/Hide
C49H54BF2N7O7
 1
1
Kd = 92 nM
   TI
   LI
   LO
   TS
CP0056538
(S)-1-hydroxymethyl-2-octanoyloxy-ethyl ester
   Show/Hide
C19H36O5
 1
1
Ki = 40.1 nM
   TI
   LI
   LO
   TS
CP0498357
bis[[3-(trifluoromethyl)phenyl]methyl] 5-(hydroxymethyl)benzene-1,3-dicarboxylate
   Show/Hide
C25H18F6O5
 1
1
Ki = 205 nM
   TI
   LI
   LO
   TS
CP0450932
diheptan-3-yl 5-(hydroxymethyl)benzene-1,3-dicarboxylate
   Show/Hide
C23H36O5
 1
1
Ki = 319 nM
   TI
   LI
   LO
   TS
CP0491085
dihexan-3-yl 5-(hydroxymethyl)benzene-1,3-dicarboxylate
   Show/Hide
C21H32O5
 1
1
Ki = 661 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0040333
2-{[2,6-dihydroxy-4-({[(3R,4R)-4-[(4-hydroxybenzene)amido]pyrrolidin-3-yl]oxy}carbonyl)phenyl]carbonyl}-3-hydroxybenzoic acid
   Show/Hide
C26H22N2O10
 1
1 IC50 = 22 nM
CP0038373
2-{[2,6-dihydroxy-4-({[(3R,4R)-3-[(4-hydroxybenzene)amido]azepan-4-yl]oxy}carbonyl)phenyl]carbonyl}-3-hydroxybenzoic acid
   Show/Hide
C28H26N2O10
 4
1 IC50 = 30 nM
2 IC50 = 70 nM
3 IC50 = 74 nM
4 Kd = 6.4 nM
CP0040070
2-{[2,6-dihydroxy-4-({[(1R,2R)-2-[(4-hydroxybenzene)amido]cyclopentyl]oxy}carbonyl)phenyl]carbonyl}-3-hydroxybenzoic acid
   Show/Hide
C27H23NO10
 1
1 IC50 = 40 nM
CP0045273
(+/-)-indolactum-V 13-Hydroxymethyl-10-isopropyl-9-methyl-3,9,12-triaza-tricyclo[6.6.1.0*4,15*]pentadeca-1,4,6,8(15)-tetraen-11-one
   Show/Hide
C17H23N3O2
 5
1 Ki = 11 nM
2 Ki = 21 nM
3 Ki = 126.9 nM
4 Ki = 140 nM
5 Ki = 4000 nM
CP0056538
(S)-1-hydroxymethyl-2-octanoyloxy-ethyl ester
   Show/Hide
C19H36O5
 1
1 Ki = 33 nM
Clinical Information about the Protein
Target 1 ( Protein kinase C alpha (PRKCA) )
Target Type Successful Target
Disease 3 Target-related Diseases  3
1 Spinal muscular atrophy [ICD-11: 8B61]
2 Nephritis [ICD-11: GB40]
3 Human immunodeficiency virus infection [ICD-11: 1C62]
Approved Drug(s) 1 Approved Drug  1
1 Sodium phenylbutyrate Approved
Spinal muscular atrophy
Discontinued Drug(s) 1 Discontinued Drug  1
1 Acteoside Terminated
Nephritis
Investigative Drug(s) 1 Investigative Drug  1
1 PROSTRATIN Investigative
Human immunodeficiency virus infection
Target 2 ( PKC-alpha messenger RNA (PRKCA mRNA) )
Target Type Literature-reported Target